MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
about
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaStructure-function analyses of the human SIX1–EYA2 complex reveal insights into metastasis and BOR syndromeA SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesisDegree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.MicroRNA-30a regulates zebrafish myogenesis through targeting the transcription factor Six1Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.The molecular mechanics of mixed lineage leukemia.Small-molecular modulators of cancer-associated epigenetic mechanisms.Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.The SIX1-EYA transcriptional complex as a therapeutic target in cancer.PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyondCell cycle control in acute myeloid leukemia.AF4 uses the SL1 components of RNAP1 machinery to initiate MLL fusion- and AEP-dependent transcription.Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma.Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia.Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged DiseaseThe phosphatase-transcription activator EYA1 is targeted by anaphase-promoting complex/Cdh1 for degradation at M-to-G1 transition.Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner.The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription programAn MLL-dependent network sustains hematopoiesis.Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells.Epigenetic roles of MLL oncoproteins are dependent on NF-κBCDK6 binds and promotes the degradation of the EYA2 proteinMLL fusion proteins link transcriptional coactivators to previously active CpG-rich promoters.The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment.The EYA-SO/SIX complex in development and disease.Menin as a hub controlling mixed lineage leukemia.Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.Six1: a critical transcription factor in tumorigenesis.Mechanisms of mixed-lineage leukemia.Initiation of MLL-rearranged AML is dependent on C/EBPαThe leukemogenic fusion gene MLL-AF9 alters microRNA expression pattern and inhibits monoblastic differentiation via miR-511 repression.Epigenetic modifiers in normal and malignant hematopoiesis.
P2860
Q27674674-5E9AFE55-3DBB-4D62-8B0F-97A8455D6CB8Q27676610-06D7C0C5-FB82-49EA-9E61-66507EF4B313Q28298834-711778F7-FFF1-4E4C-8880-73BB5690C4D4Q30300029-DF41A7BD-8013-476B-B2BF-84B434020722Q30409822-5CFFE34B-4331-4783-8BC3-33E3CE628A00Q33613370-CBD939B4-5D15-4C23-AE63-8283B89E0A7AQ33842529-DE97B581-EDC0-455D-BE82-D67D097E0C5FQ34283431-C28BAB3A-8725-43A3-A359-F4C730F818A5Q34310186-F562D538-0C49-452C-AD04-7E18947860DFQ34318280-7CE02B44-8C96-4454-8AB8-41034BF5C502Q34516051-97E6A337-955C-4CCA-9242-598DAC5943EAQ34628002-FCC63497-9521-4334-BC4D-B834136E14EAQ35018755-38967332-000C-4562-B95E-CA5BEF9AB966Q35107900-516D7E14-9E54-40B2-B9BC-9D3627E9B559Q35541213-3DBE3726-FDC3-42B0-9305-AC1C3C9C1B1BQ35967446-722F2E4F-3747-42EB-BA1E-06483B688192Q36206479-749C15EF-DC10-40B1-91DD-C48F7B847AC5Q36357060-9CB0E7C7-5531-4925-BC2B-60CD4E896D03Q36545556-83892642-0634-41F4-A149-4CB3E4515DA6Q36585150-86F0CC34-CB41-4C10-AF6C-50E19A4B24C0Q36730426-208DDE0B-09AB-4F5D-9D39-8323F168283FQ36735211-7A5BAB04-CA50-407A-946C-BCB63DF3176EQ36757059-2A04D981-5D92-4B9C-B7BF-9F72B1A790D2Q36795534-D057A6B3-3176-4772-ABD1-6ABE58CAE4A5Q36892595-CD418419-3006-4E61-8E0E-B442A3D7D61EQ36906949-E1784729-29F6-4DDF-865B-3B7ADAF50F00Q37031831-DBA94CA9-09BB-4439-872E-62CE6CA2CB07Q37186452-5374846E-094A-4EFF-9816-398B4477CCDDQ37277091-5AA088DA-119F-4181-943A-EB6927952B95Q37587030-73D863E7-354D-4A95-B178-FBB6551803DFQ37701261-FB917A56-D8C1-451B-8B3E-0038511BA33CQ37727786-1FFFCCF9-7D29-453F-9594-85C680F47443Q38027074-13B7A3C1-1D33-421E-B127-0D203D578EF8Q38029260-4D99674E-3D64-422F-9CA8-0A3B19C0E0CFQ38161393-054CA237-189D-457E-8101-64FF1EEBDAC3Q38184513-A4F73E3D-3BCB-4F2B-A03F-5176FF35AF6BQ38190545-9FF26E81-4C36-41D0-861F-8365F641EC9AQ38310200-0A654D2B-5673-4BBA-94C4-AF5615096B82Q38452459-26FB0138-FD3E-4C14-8D6B-135276FDD0B3Q38459868-099607EF-1DA3-4B09-BFF3-58C1EA730D5B
P2860
MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
MLL fusion proteins preferenti ...... genes in the leukemic genome.
@ast
MLL fusion proteins preferenti ...... genes in the leukemic genome.
@en
type
label
MLL fusion proteins preferenti ...... genes in the leukemic genome.
@ast
MLL fusion proteins preferenti ...... genes in the leukemic genome.
@en
prefLabel
MLL fusion proteins preferenti ...... genes in the leukemic genome.
@ast
MLL fusion proteins preferenti ...... genes in the leukemic genome.
@en
P2093
P2860
P1433
P1476
MLL fusion proteins preferenti ...... genes in the leukemic genome.
@en
P2093
Hongkai Ji
Jingfang Dong
Joseph J Kaberlein
Michael J Thirman
Qian-Fei Wang
Roger T Luo
Ryan Mattison
P2860
P304
P356
10.1182/BLOOD-2010-12-324699
P407
P577
2011-04-25T00:00:00Z